An Open-Label Study To Determine Safety, Tolerability And Efficacy Of Long -Term Oral Lacosamide (LCM) As Adjunctive Therapy In Children With Epilepsy
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2018
At a glance
- Drugs Lacosamide (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Therapeutic Use
- Sponsors UCB
- 14 Feb 2018 This trial has been completed in Italy.
- 08 Feb 2018 Planned End Date changed from 1 May 2022 to 1 Jul 2022.
- 08 Feb 2018 Planned primary completion date changed from 1 May 2022 to 1 Jun 2022.